Analyst consensus rating
Neumora Therapeutics Analyst Rating: none
Direct answer
Neumora Therapeutics's consensus rating is none.
7 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $6.14.
Forecast evidence checked October 3, 2026.
Get free Neumora Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $0.50
- Average price target
- $6.14
- High price target
- $14.00
- Low price target
- $3.00
- Low target gap
- +500.1%
- Target upside
- +1,128.8%
- High target gap
- +2,700.6%
- Target range width
- 2,200.4%
- Consensus rating
- none
- Analysts
- 7
- Evidence date
- October 3, 2026
- Valid through
- October 10, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Neumora Therapeutics?
Neumora Therapeutics has a verified none consensus. The same dataset has an average price target of $6.14.
How far are Neumora Therapeutics's low and high targets from the recorded price?
The low target implies +500.1%, while the high target implies +2,700.6%.
How many analysts are included in Neumora Therapeutics's consensus?
The verified consensus includes 7 analysts.
How is Neumora Therapeutics's target upside or downside calculated?
The average target of $6.14 is divided by the recorded price of $0.50, then one is subtracted to produce +1,128.8%. This does not guarantee a future return.
When was Neumora Therapeutics's analyst forecast verified?
The data was verified on 2026-10-03. The dataset is valid through 2026-10-10.